Working… Menu

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02576275
Recruitment Status : Withdrawn (The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.)
First Posted : October 15, 2015
Last Update Posted : October 16, 2018
Information provided by (Responsible Party):
Verastem, Inc.

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016